Last updated: about 1 month ago
AstraZeneca’s CALYPSO Trial Report: Eneboparatide Shows Promise for Chronic Hypoparathyroidism
AstraZeneca's Form 6-K details the CALYPSO trial results for eneboparatide, indicating significant potential for treating chronic hypoparathyroidism. Key findings and next steps outlined.